Literature DB >> 3429833

Expression of pre-S gene-encoded proteins in liver and serum during chronic hepatitis B virus infection in comparison to other markers of active virus replication.

S Hadziyannis1, G Raimondo, C Papaioannou, C Anastassakos, D Wong, J Sninsky, D Shafritz.   

Abstract

Pre-S gene-encoded proteins of the hepatitis B virus (HBV) were studied in the liver by immunofluorescence and in serum by radioimmunoassay in 30 patients with chronic HBV infection. The results were compared with molecular hybridization analysis of HBV-DNA in liver and serum, with serum hepatitis B e antigen/antibody (HBeAg/anti-HBe) status and with underlying liver histology. Pre-S peptides were detected in the serum of 11 patients, 10 of whom were positive for serum HBV-DNA and/or liver hepatitis B core antigen. Only 4 of these patients were HBeAg positive. The prevalence of serum pre-S among HBV replicating carriers was 59% (10/17) compared to only 8% (1/13) among those with non-replicating virus (P less than 0.01). All patients with circulating pre-S peptides had active liver disease. Anti-pre-S was detected in the serum of only 4 patients, 3 with integrated HBV-DNA. In contrast to serum findings, pre-S peptides were detected in the liver of all patients with histochemically demonstrable hepatitis B surface antigen (HBsAg), regardless of HBV replicative status. HBsAg carriers with integrated HBV-DNA had abundant cytoplasmic pre-S1 and pre-S2 localized in numerous ground-glass hepatocytes. It is concluded that pre-S peptides are usually displayed in the liver simultaneously with histochemically detectable HBsAg; they are secreted in the serum in association with high HBV replication and release of HBV particles, but in the absence of episomal HBV replication, pre-S peptides seem to be largely retained within hepatocytic membranes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3429833     DOI: 10.1016/s0168-8278(87)80029-6

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

1.  Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state".

Authors:  Stephanos J Hadziyannis
Journal:  Hepatol Int       Date:  2007-06       Impact factor: 6.047

2.  Immunohistochemical study of pre-S(2) antigen in liver and serum of patients with chronic hepatitis B.

Authors:  K Takaguchi; G Yamada; T Tsuji
Journal:  Gastroenterol Jpn       Date:  1990-06

3.  New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection.

Authors:  F Zoulim; L Mimms; M Floreani; C Pichoud; I Chemin; A Kay; L Vitvitski; C Trepo
Journal:  J Clin Microbiol       Date:  1992-05       Impact factor: 5.948

4.  Immunogenicity of a recombinant Pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster.

Authors:  B Bucher; P Francioli; B Geudelin; B Fritzell; D Lavanchy; P C Frei
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-03       Impact factor: 3.267

5.  High prevalence of hepatitis B virus pre-s mutant in countries where it is endemic and its relationship with genotype and chronicity.

Authors:  Tran Thien-Tuan Huy; Hiroshi Ushijima; Khin Maung Win; Pairoj Luengrojanakul; Pradeep Krishna Shrestha; Zhao-Hua Zhong; Andrei V Smirnov; Teresa Casanovas Taltavull; Tetsutaro Sata; Kenji Abe
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

6.  Intrahepatic expression of pre-S1 and pre-S2 antigens in chronic hepatitis B virus infection in relation to hepatitis B virus replication and hepatitis delta virus superinfection.

Authors:  C M Chu; Y F Liaw
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

7.  Detection of hepatitis B virus pre-S1 and pre-S2 determinants in paraffin wax embedded liver tissue: importance of reagents used.

Authors:  N Hadzic; A Alberti; B Portmann; D Vergani
Journal:  J Clin Pathol       Date:  1991-07       Impact factor: 3.411

8.  Evaluation of the pre-S (pre-S(1)Ag/pre-S(2)Ab) system in hepatitis B virus infection.

Authors:  M I Galán; J Tomás; M C Bernal; F J Salmerón; M C Maroto
Journal:  J Clin Pathol       Date:  1991-01       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.